Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study

This publication has 23 references indexed in Scilit:

• Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
  New England Journal of Medicine, 2012
• Clinical Implications of Novel Mutations in Epigenetic Modifiers in AML
  Hematology/Oncology Clinics of North America, 2011
• Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study
  Leukemia & Lymphoma, 2011
• MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
  Blood, 2009
• Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials
  British Journal of Haematology, 2009
• Azacitidine prolongs overall survival and reduces infections and hospitalisations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: An update
  ecancermedicalscience, 2009
• Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia
  Haematologica, 2008
• Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia
  Cancer, 2007
• Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
  Journal of Clinical Oncology, 2003
• The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial
  Blood, 2001